T Cells
T cells play a central role in cell-mediated immunity and immunotherapy based on these powerful cells is a rapidly growing field with promising results. Current therapies use one of four technologies to confer therapeutic benefit: chimeric antigen receptor (CAR) bearing T cells, tumor-infiltrating lymphocytes (TILs), regulatory T cells (Treg) and T cell receptor (TCR) engineered T cells. There are currently five approved chimeric antigen receptor (CAR) T cell therapies, and one T cell receptor (TCR) therapy. These treatments take advantage of the killing function of the T cells, engineering them to recognize antigens on the surface of cancer cells. While the first T cell therapies target “liquid” cancers such as lymphomas and leukemias, the first treatment for a solid tumor was recently approved and hundreds of clinical trials are underway. Trailblazing work is being done to expand the diseases that may be treated with T cell-based therapies including chronic infection and autoimmunity.
To ensure a seamless transition from preclinical development to commercial manufacturing, we offer CellGenix® cytokines and growth factors both in GMP and preclinical grade.
Our GMP cytokines are provided with documented evidence of purity, potency, consistency and stability. In combination with our expert regulatory and technical support this will help simplify your raw material qualification and validation efforts.
CellGenix® GMP recombinant cytokines are produced following all applicable GMP guidelines and allow for the safe use in accordance with USP Chapter <1043>, Ph. Eur. General Chapter 5.2.12 and ISO 20399:2022.
T Cells
T cells play a central role in cell-mediated immunity and immunotherapy based on these powerful cells is a rapidly growing field with promising results. Current therapies use one of four technologies to confer therapeutic benefit: chimeric antigen receptor (CAR) bearing T cells, tumor-infiltrating lymphocytes (TILs), regulatory T cells (Treg) and T cell receptor (TCR) engineered T cells. There are currently five approved chimeric antigen receptor (CAR) T cell therapies, and one T cell receptor (TCR) therapy. These treatments take advantage of the killing function of the T cells, engineering them to recognize antigens on the surface of cancer cells. While the first T cell therapies target “liquid” cancers such as lymphomas and leukemias, the first treatment for a solid tumor was recently approved and hundreds of clinical trials are underway. Trailblazing work is being done to expand the diseases that may be treated with T cell-based therapies including chronic infection and autoimmunity.
To ensure a seamless transition from preclinical development to commercial manufacturing, we offer CellGenix® cytokines and growth factors both in GMP and preclinical grade.
Our GMP cytokines are provided with documented evidence of purity, potency, consistency and stability. In combination with our expert regulatory and technical support this will help simplify your raw material qualification and validation efforts.
CellGenix® GMP recombinant cytokines are produced following all applicable GMP guidelines and allow for the safe use in accordance with USP Chapter <1043>, Ph. Eur. General Chapter 5.2.12 and ISO 20399:2022.
Test Growth Factor and Cytokines Samples for T Cells
Samples for cell and gene therapy as well as regenerative medicine.
T Cell Growth Factors and Cytokines | ||
|---|---|---|
IL-2 | More Info | Visit eShop |
IL-7 | More Info | Visit eShop |
IL-15 | More Info | Visit eShop |
IL-21 | More Info | Visit eShop |
TGF-β1 | ||
IL-2
CellGenix® Recombinant Human Interleukin-2 (IL-2) is an animal-derived component-free product. It reliably activates and expands T cells, natural killer cells (NK cells) and cytokine-induced killer cells (CIK cells). CellGenix® rh IL-2 preclinical grade and GMP grade are both produced in a dedicated animal-free GMP facility.
General Information
IL-2 is a cytokine signaling molecule that is mainly produced by T cells. It is a central regulator of immune responses and plays a role in anti-inflammatory reactions, hematopoiesis and tumor surveillance.
IL-2 is used in the cell and gene therapy space to promote proliferation and differentiation of CAR T cells, TCR T cells, Tregs, TILs, NK cells and CIK cells.
IL-7
CellGenix® Recombinant Human Interleukin-7 (IL-7) is an animal-derived component-free product. It supports the survival, proliferation and differentiation of T cells and enhances survival of natural killer cells (NK cells). CellGenix® rh IL-7 preclinical grade and GMP grade are both produced in a dedicated animal-free GMP facility.
General Information
IL-7 is a cytokine that promotes the differentiation of pluripotent hematopoietic stem cells (HSCs) into lymphoid progenitor cells. Furthermore, it supports proliferation of various cells in the lymphoid lineage (B cells, T cells and NK cells). It is secreted mainly by stromal cells in the bone marrow and thymus.
IL-7 is used in the cell and gene therapy space for the ex vivo expansion of genetically modified T cells, such as CAR T cells, and differentiation of induced pluripotent stem cells (iPSCs) into T cells. It is in addition used to differentiate cord blood derived hematopoietic stem cells (HSCs/CD34+) into NK cells.
IL-15
CellGenix® Recombinant Human Interleukin-15 (IL-15) is an animal-derived component-free product. It promotes the proliferation of T cells and stimulates the proliferation of natural killer cells (NK cells) as well as the generation of cytokine-induced killer cells (CIK cells). CellGenix® rh IL-15 preclinical grade and GMP grade are both produced in a dedicated animal-free GMP facility.
General Information
IL-15 is a cytokine that plays an important role in humoral and adaptive immune responses. It induces or enhances the differentiation, maintenance, or activation of NK cells and multiple T cell subsets. IL-15 is produced by a large number of cell types, including monocytes, macrophages, dendritic cells, keratinocytes, fibroblasts and nerve cells.
IL-15 is used in the cell and gene therapy space for the ex vivo expansion of various T cells (CAR T cells, TCR T cells and TILs) as well as NK cells and the generation of CIK cells.
IL-21
CellGenix® Recombinant Human Interleukin-21 (IL-21) is an animal-derived component-free product. It reliably promotes the proliferation of T cells and natural killer cells (NK cells) and enhances their cytotoxic function. CellGenix® rh IL-21 preclinical grade and GMP grade are both produced in a dedicated animal-free GMP facility.
General Information
IL-21 is a cytokine that plays an important role in humoral and adaptive immune responses. It stimulates the proliferation of NK cells and multiple T cell subsets, especially cytotoxic T cells. It is produced by activated CD4+ T helper cells and NK T cells.
IL-21 is used in the cell and gene therapy space for the ex vivo expansion of T cells, including CAR T cells and TCR T cells and NK cells.
TGF-β1
CellGenix® Recombinant Human Transforming Growth Factor-beta 1 (TGF-β1) is an animal-derived component-free product. It reliably promotes the expansion of induced pluripotent stem cells (iPSC), embryonic stem cells (ESC), mesenchymal stem cells (MSC) as well as regulatory T cells (Tregs). It also stimulates the differentiation of T cells into Tregs. CellGenix® rh TGF-β1 preclinical grade and GMP grade are both produced in a dedicated GMP facility.
General Information
TGF-β1 is a member of the growth factor beta superfamily and plays a role in various cellular functions like cell differentiation, proliferation and apoptosis. It is secreted by most immune cells and especially interacts with T cells, B cells, macrophages and monocytes.
TGF-β1 is used in the cell and gene therapy space to promote expansion of iPSC, ESC, MSC and Tregs.
CellGenix® Recombinant Human TGF-β1 is produced using a human amniocyte cell line (CAP®). By using the CAP® technology we are able to produce this difficult to express glyco-protein with authentic human post-translational modifications. These human post-translational modifications are not accessible by bacterial expression.
